TYK2 and psoriasis: Deucravacitinib (Deu), a first‐in‐class oral Tyrosine kinase 2 (TYK2) inhibitor, has demonstrated favorable therapeutic outcomes in real‐world clinical practice for the treatment of psoriasis compared to many oral therapies such as methotrexate and apremilast.[6, 7] Deu stabilizes the TYK2 pseudokinase (JH2) domain through allosteric inhibition, disrupting the interaction between TYK2's regulatory and catalytic domains.